rivastigmine has been researched along with galantamine in 302 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 142 (47.02) | 29.6817 |
| 2010's | 122 (40.40) | 24.3611 |
| 2020's | 38 (12.58) | 2.80 |
| Authors | Studies |
|---|---|
| Brossi, A; Greig, NH; Holloway, HW; Whittaker, NF; Yu, QS; Zhu, X | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Alley, GM; Brossi, A; Deschamps, JR; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, D; Yu, QS; Zhan, M | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, DA; Shafferman, A; Tweedie, D; Yu, QS | 1 |
| Decker, M; Lehmann, J; Rommelspacher, H; Schott, Y | 1 |
| Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Agnusdei, M; Belinskaya, T; Borriello, M; Brindisi, M; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fiorini, I; Gemma, S; Nacci, V; Novellino, E; Panico, A; Persico, M; Ros, S; Saxena, A | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Al-Rashid, ZF; Hsung, RP | 2 |
| Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Bazureau, JP; Burgy, G; Carreaux, F; Cochet, C; Delhommel, F; Durieu, E; Elkins, JM; Filippakopoulos, P; Knapp, S; Lo, DC; Meijer, L; Oberholzer, AE; Pearl, LH; Schmid, RS; Soundararajan, M; Tahtouh, T | 1 |
| Carotti, A; Catto, M; Cellamare, S; Leonetti, F; Nicolotti, O; Pesce, P; Pisani, L; Stefanachi, A | 1 |
| Brůčková, L; Imramovský, A; Jampílek, J; Královec, K; Mandíková, J; Pejchal, V; Šimůnek, P; Štěpánková, Š; Trejtnar, F; Vančo, J; Vorčáková, K | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Adam, BL; Gao, J; Terry, AV | 1 |
| Krátký, M; Štěpánková, Š; Vinšová, J; Vorčáková, K | 1 |
| Amooru, GD; Ampasala, DR; Darla, MM; Devineni, SR; Eadlapalli, S; Kotapati, KV; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Brazzolotto, X; Chan, S; De la Mora, E; Deora, GS; Dighe, SN; Nachon, F; Parat, MO; Ross, BP | 1 |
| Dag, A; Durdagi, S; Gazioglu, I; Kayık, G; Kurt, BZ; Salmas, RE; Sonmez, F | 1 |
| Krátký, M; Navrátilová, L; Štěpánková, Š; Stolaříková, J; Trejtnar, F; Vinšová, J; Vorčáková, K | 1 |
| Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A; Podkowa, A; Sałat, K; Šink, R; Stojan, J; Trontelj, J; Žakelj, S; Živin, M | 1 |
| Ibrar, A; Khan, I; Saeed, F; Shehzadi, SA | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Kumar, A; Mishra, P; Panda, G | 1 |
| Cui, Z; Gao, J; Geng, H; Li, D; Li, H; Zhou, B; Zhou, L | 1 |
| Stahl, SM | 2 |
| Giacobini, E | 1 |
| Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N | 2 |
| Farlow, MR | 2 |
| Hake, AM | 1 |
| Slagle, MA | 1 |
| Winblad, B | 1 |
| Sternon, J; Ventura, M | 1 |
| Gasser, T; Gasser, US | 1 |
| Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O | 1 |
| Robert, P | 1 |
| Rösler, M | 1 |
| Inglis, F | 1 |
| Ott, BR | 1 |
| Howard, R; Sauer, J | 1 |
| Kamei, H; Nabeshima, T; Noda, Y | 1 |
| Amici, S; Andreasen, N; Antognelli, C; Blennow, K; Davidsson, P; Gallai, V; Lanari, A; Minthon, L; Parnetti, L; Pottel, H; Romani, C | 1 |
| Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D | 1 |
| Farlow, M | 1 |
| Albuquerque, EX; Christner, C; Fehrenbacher, A; Höffle, A; Jostock, R; Lübbert, H; Ludwig, J; Maelicke, A; Pereira, EF; Radina, M; Samochocki, M; Ullmer, C; Zerlin, M | 1 |
| Doody, RS | 1 |
| Butler, R; Prabhakaran, P; Warner, J | 1 |
| Bonelli, RM | 1 |
| Fuchsberger, T; Hampel, H; Möller, HJ | 1 |
| Alhainen, K | 1 |
| Kaufer, DI | 2 |
| Haen, E; Ibach, B | 1 |
| Alisky, JM | 1 |
| Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G | 1 |
| Rioux, S | 1 |
| Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E | 1 |
| Prasher, VP | 1 |
| Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T | 1 |
| Birks, J; Evans, JG; Wilcock, G | 1 |
| Kurz, A; Van Baelen, B | 1 |
| van Dyck, CH | 1 |
| Herrmann, N; Lanctôt, KL; Thompson, S | 1 |
| Caricati-Neto, A; D'angelo, LC; Garcia, AG; Hyppolito Jurkiewicz, N; Jurkiewicz, A; Reuter, H | 1 |
| Edwards, K; Gorman, C; Therriault O'connor, J | 1 |
| Aguglia, E; Maso, E; Onor, ML; Saina, M | 1 |
| Erkinjuntti, T; Gauthier, S; Román, G | 1 |
| Tenovuo, O | 1 |
| Arya, P; Butler, R; Warner, J | 2 |
| Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D | 1 |
| Garre-Olmo, J; Gelada-Batlle, E; Hernández-Ferràndiz, M; Isern-Vila, A; López-Pousa, S; Lozano-Gallego, M; Majó-Llopart, J; Morante-Muñoz, V; Pericot-Nierga, I; Turon-Estrada, A; Vilalta-Franch, M | 1 |
| Bermudez, I; Groot-Kormelink, PJ; Smulders, CJ; van Kleef, RG; Vijverberg, HP; Zwart, R | 1 |
| Ellis, JM | 1 |
| Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N | 1 |
| Bullock, R; Dengiz, A | 1 |
| Aisen, PS | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Beck-Bornholdt, HP; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T | 1 |
| Arias, E; Gallego-Sandín, S; García, AG; López, MG; Villarroya, M | 1 |
| O'Neill, MF | 1 |
| Lublin, HK; Olsen, CE; Poulsen, HD | 1 |
| Cummings, JL | 1 |
| Jelic, V; Kivipelto, M; Winblad, B | 1 |
| Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A | 2 |
| Burns, A; Olde Rikkert, MG; Oude Voshaar, RC | 1 |
| Davis, B; Sadik, K | 1 |
| Birks, J | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Cummings, JL; Ringman, JM | 1 |
| Nourhashémi, F | 1 |
| Gilbert, S; Kergoat, MJ; Kerneis, S; Legrain, S; Vantelon, C; Wolmark, Y | 1 |
| Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K | 1 |
| Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN | 1 |
| Ancoli-Israel, S; Cooke, JR; Corey-Bloom, J; Fiorentino, L; Harrison, T; Liu, L; Loredo, JS; Marler, M | 1 |
| Blennow, K; de Leon, MJ; Zetterberg, H | 1 |
| Verhey, FR | 1 |
| Johannsen, P | 1 |
| Geyer, H; Schänzer, W; Thevis, M; Wilkens, F | 1 |
| Ieni, J; Maurice, T; Meunier, J | 1 |
| Schneeweiss, S; Thacker, EL | 1 |
| Chilovi, BV; Costardi, D; Franzoni, S; Padovani, A; Rozzini, L; Trabucchi, M | 1 |
| Agbokou, C; Ferreri, F; Gauthier, S | 1 |
| Bhasin, M; Edwards, K; McKeith, I; Rowan, E | 1 |
| Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F | 1 |
| Aerssens, J; Alvidrez, J; Anand, R; Faison, WE; Farrer, LA; Jarvik, L; Manly, J; McRae, T; Mintzer, JE; Murphy, GM; Olin, JT; Regier, D; Sano, M; Schultz, SK | 1 |
| Ballard, CG; Chalmers, KA; Love, S; McKeith, IG; O'Brien, JT; Perry, EK; Todd, C; Wilcock, G | 1 |
| Egert, S; Förstl, H; Wagenpfeil, S | 1 |
| Basun, H; Cederholm, T; Eriksdotter-Jönhagen, M; Faxén-Irving, G; Freund-Levi, Y; Garlind, A; Grut, M; Palmblad, J; Vedin, I; Wahlund, LO | 1 |
| Bonham, J; Connelly, PJ; Cousland, G; Prentice, NP | 1 |
| Baker, AS; Brandt, J; Lyketsos, CG; Mayer, LS; McNabney, M; Onyike, CU; Rosenblatt, A; Samus, QM | 1 |
| Kavirajan, H; Schneider, LS | 1 |
| Anghelescu, I; Heuser, I | 1 |
| Green, C | 1 |
| McCain, KR; Sawyer, TS; Spiller, HA | 1 |
| Neno, R | 1 |
| Lang, CJ | 1 |
| Kircher, T; Leucht, S; Thienel, R; Voss, B | 1 |
| Bagheri, H; Lapeyre-Mestre, M; Montrastruc, JL; Sommet, A; Tavassoli, N | 1 |
| Bajda, M; Malawska, B; Musiał, A | 1 |
| Bogetto, F; Marino, F; Montemagni, C; Perrone, D; Rocca, P | 1 |
| Gorelick, PB; Nyenhuis, DL | 1 |
| Landmark, K; Reikvam, A | 1 |
| Adelman, A; Campos-Outcalt, D; Cross, JT; Forciea, MA; Hopkins, R; Mehr, D; Owens, DK; Qaseem, A; Santaguida, P; Schellhase, K; Shekelle, P; Snow, V | 1 |
| Booker, L; Cowan, D; Ismaila, A; Levine, M; Oremus, M; Patterson, C; Raina, P; Santaguida, P | 1 |
| Downey, D | 1 |
| Liao, S; Morrison, LJ | 1 |
| Shimohama, S | 2 |
| Graham, L | 1 |
| Dartigues, JF; Fourrier-Réglat, A; Helmer, C; Merliere, Y; Moore, N; Pariente, A | 1 |
| Graham, K; Josif, S | 1 |
| Cuffel, B; Del Valle, M; Mark, TL; McRae, T; Mucha, L; Shaohung, S | 1 |
| Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP | 1 |
| Reid, RT; Sabbagh, MN | 1 |
| Boucher, JM; Charbonneau, C; Dorais, M; LeLorier, J; Lescrauwaet, B; Massoud, F | 1 |
| Chen, SH; Hsieh, YH; Lin, PC; Yang, YH; Yeh, HH | 1 |
| Darreh-Shori, T; Eagle, G; Lane, R; Mousavi, M; Nordberg, A; Peskind, E; Soininen, H | 1 |
| Blais, L; Forget, A; Kergoat, MJ; Kettani, FZ; Leroux, JC; Perreault, S | 1 |
| Jurivich, DA; Patel, AR; Perez, F; Zhou, X | 1 |
| Ehret, A; Feuerstein, TJ; Förster, S; Jackisch, R; Kammerer, M; Rothmaier, AK; Zentner, J | 1 |
| Crutchfield, D | 1 |
| Smith, DA | 1 |
| Lane, R; Venneri, A | 1 |
| Morgan, S; Rodda, J; Walker, Z | 1 |
| Binder, C; Camacho, F; Dalziel, W; Herrmann, N; Smyth, S | 1 |
| Tang, XC; Wang, J; Zhang, HY | 1 |
| Dominguez, J; Gauthier, S; Homma, A; Ikeda, M; O'Connor, D; Suh, GH; Wimo, A; Yang, BM | 1 |
| Alfonso, V; González-Adalid, M; Jiménez Caballero, PE; Sevilla, C | 1 |
| Adler, M; Akkerman, M; Albuquerque, EX; Aracava, Y; Pereira, EF | 1 |
| Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV | 1 |
| Kelly, S; Lockhart, IA; Mitchell, SA | 1 |
| Leifer, BP | 1 |
| Bagnoli, S; Bellavista, E; Benussi, L; Binetti, G; Chiamenti, AM; Crepaldi, G; Cruciani, G; Di Iorio, A; Feraco, E; Franceschi, C; Gabelli, C; Ghidoni, R; Gianni, W; Ginestroni, A; Grimaldi, LM; Marchegiani, F; Minicuci, N; Mishto, M; Nacmias, B; Olivieri, F; Paganelli, R; Santoro, A; Scarpino, O; Scognamiglio, M; Siviero, P; Sorbi, S | 1 |
| Freedman, M; Kaye, ED; Petrovic-Poljak, A; Verhoeff, NP | 1 |
| Calciano, MA; Einstein, R; Snyder, PJ; Zhou, W | 1 |
| Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D | 1 |
| Gadzhanova, S; Mackson, J; Roughead, L | 1 |
| Londos, E; Minthon, L; Wallin, AK; Wattmo, C | 1 |
| Borah, B; Sacco, P; Zarotsky, V | 1 |
| Dautzenberg, L; Dautzenberg, PL; Thissen, A; Wouters, CJ | 1 |
| Criado-Alvarez, JJ; Romo Barrientos, C | 1 |
| Egberts, T; Kröger, E; Souverein, P; van Marum, R | 1 |
| Attard, A; Jacobsen, P; Patel, SS; Shergill, S | 1 |
| Osborn, GG; Saunders, AV | 1 |
| Desmarais, JE; Gauthier, S; Massoud, F | 1 |
| Mets, T; Van Puyvelde, K | 1 |
| Kinnair, D; Machili, C; Prettyman, R; Van Diepen, E | 1 |
| Hüll, M; Voigt-Radloff, S | 1 |
| Bohlken, J; Selke, GW; van den Bussche, H | 1 |
| Kremer, J | 1 |
| Barbujani, G; Chianella, C; Fuselli, S; Gragnaniello, D; Maisano Delser, P; Sette, E; Tola, MR; Visentini, MF | 1 |
| Barone, E; Butterfield, DA; Mancuso, C; Preziosi, P; Siciliano, R | 1 |
| Yanagisawa, K | 1 |
| Okochi, M; Takeda, M; Tanaka, T | 1 |
| Anderson, G; Austin, PC; Gill, SS; Gruneir, A; Reimer, CL; Rochon, PA; Seitz, DP | 1 |
| Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S | 1 |
| Atri, A | 1 |
| Jayaram, MB; Kour, K; Singh, J | 1 |
| Aisen, PS; Cummings, J; Schneider, LS | 1 |
| Ansermot, N; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Gray, SL; McDermott, CL | 1 |
| Isaac, M; Klugman, A; Naughton, DP; Petroczi, A; Shah, I; Tabet, N | 1 |
| Anderson, R; Bond, M; Davis, S; Hoyle, M; Hyde, C; Jeffreys, M; Miners, A; Moxham, T; Peters, J; Rogers, G; Thokala, P; Wailoo, A | 1 |
| Nakamura, Y | 1 |
| Ateskan, U; Bozoglu, E; Isik, AT; Soysal, P; Yay, A | 1 |
| Imramovsky, A; Jampilek, J; Monreal-Ferriz, J; Pauk, K; Stepankova, S; Vanco, J; Vinsova, J | 1 |
| Minthon, L; Wallin, AK; Wattmo, C | 2 |
| Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; van Marum, R | 1 |
| Eap, CB; Noetzli, M | 1 |
| Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F | 1 |
| Johnell, K; Sonde, L | 1 |
| Gard, PR; Isaac, M; Klugman, A; Richardson, C; Tabet, N | 1 |
| Londos, E; Minthon, L; Paulsson, E; Wattmo, C | 1 |
| Hattori, H | 1 |
| Peters, KR | 1 |
| Arizaga, RL; Demey, I; Rojas, G | 1 |
| Farlow, M; Ferris, SH | 1 |
| Ashoor, HM; Berliner, S; Chen, MH; Hemmelgarn, B; Ho, JM; Ng, CH; Soobiah, C; Straus, SE; Tricco, AC | 1 |
| Cumbo, E; Ligori, LD | 1 |
| Mullangi, R; Ponnayyan Sulochana, S; Sharma, K; Sukumaran, SK | 1 |
| Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Castagna, A; Cotroneo, AM; De Palo, G; Fabbo, A; Forgione, L; Gareri, P; Giacummo, A; Lacava, R; Marino, S; Putignano, D; Putignano, S; Simone, M; Zurlo, A | 1 |
| Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC | 1 |
| Shoji, M | 1 |
| Akaishi, T | 1 |
| Utsumi, K | 1 |
| Fujii, M; Sasaki, H | 1 |
| Ahnaou, A; Drinkenburg, WH; Huysmans, H; Jacobs, T | 1 |
| Chukhlovina, ML | 1 |
| Dautzenberg, PJ; Golüke, NM; Jessurun, N; Keijsers, CJ; van Strien, AM | 1 |
| Cascavilla, L; D'Onofrio, G; Fontana, A; Gravina, C; Greco, A; Paroni, G; Pellegrini, F; Pilotto, A; Seripa, D; Urbano, M | 1 |
| Eichler, T; Hertel, J; Hoffmann, W; Kilimann, I; Michalowsky, B; Teipel, S; Thyrian, JR; Wucherer, D | 1 |
| Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; Van Marum, R | 1 |
| Bozoglu, E; Cintosun, U; Doruk, H; Kocak, N; Naharci, MI; Ozturk, A; Tasci, I; Yasar, H | 1 |
| Hsieh, CY; Iwata, I; Kao Yang, YH; Lai, EC; Setoguchi, S; Wong, MB; Zhang, Y | 1 |
| Huang, AR; Redpath, CJ; van Walraven, C | 1 |
| Heinrich, S; Hertel, J; Hoffmann, W; Meyer, S; Michalowsky, B; Schaefer-Walkmann, S; Thyrian, JR; Wübbeler, M; Wucherer, D | 1 |
| Chou, YJ; Chow, LH; Hu, HY; Huang, N; Li, CP; Wang, PN; Wu, CY | 1 |
| Chamberlin, KW; Ehret, MJ | 1 |
| Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Laroche, ML; Mouls, M; Souverein, P; van Marum, R; Wilchesky, M | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 1 |
| Aref, H; Bassil, N; diTommaso, S; Kandiah, N; Lee, JH; Pai, MC; Srinivasan, AV; Yuksel, O | 1 |
| Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR | 1 |
| Lewis, SJ; Szeto, JY | 1 |
| Kobayashi, H; Nakagawa, R; Ohnishi, T; Yoshizawa, K | 1 |
| Bezerra da Silva, C; Dalarmi, L; Dallarmi Miguel, M; de Fátima Gaspari Dias, J; de Oliveira, M; Elifio-Esposito, S; Fialho do Nascimento, K; Gomes Miguel, O; Moura Burci, L; Pott, A; Warumby Zanin, SM | 1 |
| Chen, YD; Hu, WL; Wang, Y; Yuan, JL; Zhang, J | 1 |
| Cantrell, FL; Pchelnikova, JL; Thornton, SL | 1 |
| Isik, AT; Soysal, P | 1 |
| Caporaso, R; Minarini, A; Rosini, M; Simoni, E | 1 |
| Matsuda, T | 1 |
| Fišar, Z; Hroudová, J; Singh, N | 1 |
| Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Abe, K; Darwish, M; Hishikawa, N; Ohta, Y; Sato, K; Takemoto, M; Yamashita, T | 1 |
| Bassett, K; Carney, G; Dormuth, CR; Fisher, A | 1 |
| Wightman, EL | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 1 |
| Boustani, MA; Callahan, CM; Campbell, NL; Fowler, N; Gao, S; Hendrie, HC; Li, L; Perkins, AJ; Skaar, TC | 1 |
| Goebert, D; Guilloux, A; Higa, J; Lu, BY; Schultz, BR; Takeshita, J; Takeshita, S | 1 |
| Avila, A; Lawler, E | 1 |
| Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D | 1 |
| Kratz, T | 1 |
| Ali, MR; Boutajangout, A; Mezei, M; Møller, SG; Sadoqi, M | 1 |
| Kaushik, V; Mikobi, E; Raji, MA; Smith, ST | 1 |
| Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL | 1 |
| Atri, A; Ballard, C; Boneva, N; Cummings, JL; Frölich, L; Molinuevo, JL; Raket, LL; Tariot, PN; Windfeld, K | 1 |
| Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H | 1 |
| Chan, TY; Chan, WC; Chiu, J; Kng, CPL; Kong, HL; Lam, LCW; Lau, KH; Law, CB; Lin, KL; Ma, SL; Poon, TK; Tam, CCW; Tang, JHY; Tang, NLS; Wat, KHY | 1 |
| Bernal-Cobo, R; Calvo-Torres, LF; Gaviria-Mendoza, A; Machado-Alba, JE; Trujillo-Quintero, PM | 1 |
| Coenen, A; Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Leitz, P; Niehues, P | 1 |
| Fleet, JL; Garg, AX; McArthur, E; Montero-Odasso, M; Patel, A; Weir, MA | 1 |
| Ahmed, M; Aleya, L; Ashraf, GM; Barreto, GE; Begum, MM; Kabir, MT; Mathew, B; Rahman, MS; Thangapandiyan, S; Uddin, MS | 1 |
| Sharma, P; Shrivastava, SK; Tripathi, MK | 1 |
| Chakkamparambil, B; Friedman, L; Grossberg, GT; Haake, A; Nguyen, K | 1 |
| Honjo, Y; Ide, K; Takechi, H | 1 |
| Aksoz, BE; Aksoz, E | 1 |
| Barthold, D; Drabo, EF; Ferido, P; Gray, SL; Joyce, G; Marcum, ZA; Zissimopoulos, J | 1 |
| Ali, N; Arora, M; Ghai, R; Grover, P; Kapoor, G; Nagarajan, K | 1 |
| Alsabbagh, MW; Huang, Y | 1 |
| Amenta, F; Ben, DD; Buccioni, M; Lambertucci, C; Marucci, G; Volpini, R | 1 |
| Bhanuprakash, K; Chitumalla, RK; Karthikraj, R; Nagaveni, V; Prabhakar, S; Vairamani, M | 1 |
| Chmielewska, K; Dzierzbicka, K; Inkielewicz-Stepniak, I; Kowalski, S; Przybyłowska, M | 1 |
| Han, E; Kalisch Ellett, L; Lee, HJ; Lee, J; Roughead, EE | 1 |
| Abdel-Daim, MM; Akhtar, MF; Albadrani, GM; Arya, A; Chahal, R; El-Seedi, HR; Kamel, M; Kaushik, D; Khalifa, SMA; Mittal, V; Rahman, MH; Rao, R; Saleem, A | 1 |
| Abdul-Rahim, AH; Battle, CE; Hewitt, J; Quinn, TJ; Shenkin, SD | 1 |
| Halminen, O; Hörhammer, I; Linna, M; Mehtälä, J; Mikkola, T; Vesikansa, A; Virta, LJ; Ylisaukko-Oja, T | 1 |
| Fitzgerald, PJ; Ghimire, A; Hale, PJ; Watson, BO | 1 |
| Durães, F; Ndongo, TM; Passos, MLC; Pinto, M; Resende, DISP; Saraiva, MLMFS; Sousa, E | 1 |
| Bu, K; Cheng, F; Morris, R; Umeukeje, G | 1 |
| Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT | 2 |
| Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X | 1 |
| Cui, Y; Ren, G; Shi, X; Xu, Z | 1 |
| Bawany, MH; Florentino, SA; Ma, HM | 1 |
| Guo, Y; Hu, Q; Jiang, Y; Li, B; Lin, JM; Yu, L | 1 |
| Chen, YS; Chien, WC; Chung, CH; Lin, CY; Lin, YC; Liu, CT; Tsai, CS; Tsai, YT; Tzeng, NS; Yang, CC | 1 |
| Bak, SH; Byeon, GH; Byun, J; Choi, HS; Chun, IK; Heo, J; Hong, Y; Jang, JW; Jeong, CW; Kasani, PH; Kim, JA; Kim, JH; Kim, JK; Kim, KL; Kim, S; Kim, WJ; Kim, Y; Kwon, SO; Lee, DY; Lee, EJ; Lee, K; Lee, SA; Moon, KW; Nam, SJ; Park, JI; Park, SW; Park, YJ; Rhee, HY | 1 |
| Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA | 1 |
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
| Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T | 1 |
| Andersen, K; Grøntved, S; Lolk, A; Nielsen, RE; Valentin, JB | 1 |
| Achten, E; Beun, S; Clement, P; Moyaert, P | 1 |
| Ando, A; Enomoto, H; Kose, E; Tate, N; Yamamoto, T; Yasuno, N | 1 |
| Yamada, M | 1 |
| Cox, GR; Haslam, R; Ure, A; Williams, K | 1 |
| Boada, M; Carnero-Pardo, C; Fortea, J; García-Ribas, G; Martínez-Lage, P; Olazarán, J; Sánchez-Juan, P; Viñuela, F | 1 |
| Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A | 1 |
| Ahuja, M; Gabor, C; Karimi, A; Lee, J; Lewis, K; Patterson, C; Reppas-Rindlisbacher, C; Siddhpuria, S; Sood, E; Wong, E | 1 |
125 review(s) available for rivastigmine and galantamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
Topics: Aldehyde Reductase; Alkaline Phosphatase; Cholinesterases; Coumarins; Drug Design; Enzymes; Glucosidases; Humans; Molecular Docking Simulation; Monoamine Oxidase | 2018 |
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands; Neuroprotective Agents | 2019 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 2000 |
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2002 |
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins | 2002 |
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2002 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Rivastigmine | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2004 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
Evidence-based pharmacotherapy of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Research Design; Rivastigmine | 2004 |
Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Multicenter Studies as Topic; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseases; Cholinesterase Inhibitors; Clinical Trials as Topic; Comorbidity; Donepezil; Double-Blind Method; Drug Evaluation; Drug Interactions; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Institutionalization; Longitudinal Studies; Male; Memantine; Meta-Analysis as Topic; Mice; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Single-Blind Method; Sleep Wake Disorders; Treatment Outcome | 2004 |
Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
Topics: Aged; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Parasympathetic Nervous System; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Cholinesterase inhibitors in the treatment of dementia.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Illness; Dementia; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2005 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine | 2004 |
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Long-Term Care; Phenylcarbamates; Piperidines; Rivastigmine | 2005 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2005 |
[Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Netherlands; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2005 |
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2005 |
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Lactones; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Sulfones; Vitamin E | 2006 |
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Circadian Rhythm; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep; Sleep, REM | 2006 |
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evidence-Based Medicine; Female; Galantamine; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome; United Kingdom | 2006 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Male; Molecular Biology; Phenylcarbamates; Piperidines; Plaque, Amyloid; Positron-Emission Tomography; Randomized Controlled Trials as Topic; Rivastigmine; tau Proteins | 2006 |
[Pharmacotherapy for Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Stroke | 2006 |
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenic Psychology; Treatment Outcome | 2006 |
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Donepezil; Ethnicity; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Thiazoles; White People | 2007 |
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publication Bias; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2007 |
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Topics: Cholinesterase Inhibitors; Databases, Bibliographic; Dementia, Vascular; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Odds Ratio; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors; Treatment Outcome | 2007 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine | 2007 |
[Are anti-dementia drugs worthwhile?].
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Therapy, Combination; Economics, Medical; Excitatory Amino Acid Antagonists; Galantamine; Germany; Health Policy; Humans; Indans; Memantine; Meta-Analysis as Topic; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Physostigmine; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Indole Alkaloids; Isoquinolines; Phenylcarbamates; Physostigmine; Piperidines; Propidium; Rivastigmine; Steroids; Tacrine | 2007 |
Diagnosis and management of vascular cognitive impairment.
Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2008 |
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Pharmacologic management of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; N-Methylaspartate; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2008 |
[Treatment of Alzheimer's disease: status quo and future considerations].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Behavioral Symptoms; Choline; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Design; Galantamine; Glutamic Acid; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Risk Factors; Rivastigmine | 2008 |
Diagnosis and treatment of dementia with Lewy bodies.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Tacrine | 2008 |
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2008 |
Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Selection; Phenylcarbamates; Piperidines; Prevalence; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Failure; United States; Withholding Treatment | 2008 |
Treatment of Alzheimer's disease in the long-term-care setting.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Long-Term Care; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2009 |
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Topics: Acetylcholine; Alkaloids; Animals; Anti-Inflammatory Agents; Cholinergic Agents; Cholinesterase Inhibitors; Dementia, Vascular; Disease Models, Animal; Donepezil; Galantamine; Humans; Indans; Inflammation; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, Cholinergic; Rivastigmine; Sesquiterpenes; Signal Transduction | 2009 |
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2009 |
Frontotemporal dementia and pharmacologic interventions.
Topics: Antidepressive Agents; Brain; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Corpus Striatum; Dopamine; Frontotemporal Dementia; Galantamine; Humans; Mental Disorders; Neuroprotective Agents; Phenylcarbamates; Receptors, Serotonin; Rivastigmine; Selegiline | 2010 |
Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Hallucinations; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration | 2010 |
Switching cholinesterase inhibitors in older adults with dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Treatment Outcome | 2011 |
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Caregivers; Donepezil; Galantamine; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Institutionalization; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
[Cholinesterase inhibitors for treating dementia. Review].
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2010 |
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Memantine; Neurons; Oxidative Stress; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Rivastigmine | 2011 |
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2011 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Japan; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2011 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Plaque, Amyloid; Rivastigmine; tau Proteins | 2012 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
Acetylcholinesterase inhibitors for schizophrenia.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology | 2012 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E | 2012 |
Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
Topics: Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depression; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2012 |
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine; Technology Assessment, Biomedical | 2012 |
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Pharmacogenetics; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Effectiveness and limitation of newly approved drugs for Alzheimer's disease].
Topics: Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Japan; Memantine; Phenylcarbamates; Quality of Life; Rivastigmine | 2013 |
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Communication Disorders; Donepezil; Galantamine; Humans; Indans; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Rivastigmine | 2013 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
[Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinergic Neurons; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Neuroprostanes; Phenylcarbamates; Piperidines; Rivastigmine | 2013 |
Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tandem Mass Spectrometry | 2014 |
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2014 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
[Memory-enhancing drugs].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Response Element-Binding Protein; Donepezil; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Galantamine; Hippocampus; Humans; Indans; Long-Term Potentiation; Memantine; Memory; Memory Disorders; Molecular Targeted Therapy; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Synaptic Transmission | 2014 |
[Progress of dementia medicine: Special reference to Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Magnetic Resonance Imaging; Memantine; Neurofibrillary Tangles; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Tomography, Emission-Computed, Single-Photon | 2014 |
[Pathogenetic mechanisms of dementia in the older patients with Parkinson's diseases].
Topics: Aging; alpha-Synuclein; Aminoquinolines; Cholinergic Neurons; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Male; Mutation; Parkinson Disease; Phenylcarbamates; Protein Kinases; Rivastigmine | 2014 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Rivastigmine; Treatment Outcome | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2016 |
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Topics: Aged; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Network Meta-Analysis; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2016 |
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Neuropsychological Tests; Piperidines; Rivastigmine | 2016 |
Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Piperidines; Rivastigmine; Structure-Activity Relationship | 2016 |
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine | 2016 |
Potential benefits of phytochemicals against Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes | 2017 |
Alzheimer Disease: Monotherapy vs. Combination Therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine | 2017 |
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Piperidines; Rivastigmine; Severity of Illness Index | 2017 |
The Diagnosis and Treatment of Behavioral Disorders in Dementia.
Topics: Attention Deficit and Disruptive Behavior Disorders; Cholinesterase Inhibitors; Dementia; Galantamine; Humans; Rivastigmine | 2017 |
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Comorbidity; Donepezil; Galantamine; Polypharmacy; Rivastigmine | 2018 |
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Medicine, Traditional; Memantine; Nootropic Agents; Piperidines; Plant Extracts; Rivastigmine | 2018 |
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Rivastigmine | 2018 |
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Repositioning; Galantamine; Humans; Rivastigmine; Tacrine | 2019 |
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Rivastigmine | 2020 |
Vital Role of Monoamine Oxidases and Cholinesterases in Central Nervous System Drug Research: A Sharp Dissection of the Pathophysiology.
Topics: Central Nervous System Agents; Central Nervous System Diseases; Cholinesterases; Combined Modality Therapy; Donepezil; Drug Design; Enzyme Inhibitors; Galantamine; Humans; Monoamine Oxidase; Rivastigmine; Structure-Activity Relationship; Tacrine | 2020 |
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Mice; Phytotherapy; Plant Preparations; Rats; Rivastigmine | 2020 |
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.
Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Rivastigmine | 2020 |
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Humans; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2021 |
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Rivastigmine; Sesquiterpenes | 2021 |
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Topics: Activities of Daily Living; Bias; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Donepezil; Galantamine; Humans; Network Meta-Analysis; Nootropic Agents; Physical Functional Performance; Placebos; Randomized Controlled Trials as Topic; Rivastigmine | 2021 |
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Topics: Activities of Daily Living; Alzheimer Disease; Amino Acids; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Ginkgo biloba; Humans; Nootropic Agents; Patient Safety; Plant Extracts; Rivastigmine | 2022 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Acetylcholinesterase inhibitors to enhance recovery from traumatic brain injury: a comprehensive review and case series.
Topics: Acetylcholinesterase; Adult; Brain Injuries, Traumatic; Child; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Piperidines; Rivastigmine | 2022 |
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropic Agents; Rivastigmine | 2022 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review.
Topics: Acetylcholinesterase; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Dementia; Galantamine; Humans; Indans; Parkinson Disease; Perfusion; Phenylcarbamates; Piperidines; Rivastigmine | 2023 |
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2023 |
Acetylcholinesterase inhibitors for autistic spectrum disorders.
Topics: Acetylcholine; Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Risperidone; Rivastigmine | 2023 |
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Sleep Initiation and Maintenance Disorders | 2023 |
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.
Topics: Accidental Falls; Accidental Injuries; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Fractures, Bone; Galantamine; Humans; Rivastigmine; Syncope | 2023 |
19 trial(s) available for rivastigmine and galantamine
| Article | Year |
|---|---|
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Galantamine; Humans; Indans; Peptide Fragments; Phenylcarbamates; Phosphorylation; Piperidines; Rivastigmine; tau Proteins | 2002 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2004 |
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2004 |
Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Injuries; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Performance; Rivastigmine; Treatment Outcome | 2005 |
Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Prospective Studies; Retrospective Studies; Rivastigmine; Severity of Illness Index; Time Factors | 2005 |
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Italy; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2005 |
Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Polysomnography; Rivastigmine; Sleep Stages; Sleep Wake Disorders | 2006 |
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors.
Topics: Activities of Daily Living; Aged; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Computer-Assisted Instruction; Donepezil; Female; Galantamine; Humans; Indans; Intelligence; Longitudinal Studies; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Nootropic Agents; Orientation; Phenylcarbamates; Piperidines; Problem Solving; Retrospective Studies; Rivastigmine; Software; Treatment Outcome | 2007 |
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Depression; Dietary Supplements; Donepezil; Double-Blind Method; Fatty Acids, Omega-3; Female; Galantamine; Genotype; Humans; Indans; Male; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Statistics, Nonparametric; Treatment Outcome | 2008 |
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cholinesterase Inhibitors; Dietary Supplements; Donepezil; Double-Blind Method; Female; Folic Acid; Folic Acid Deficiency; Galantamine; Homocysteine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Placebos; Rivastigmine; Treatment Outcome; Vitamin B Complex; Vitamins | 2008 |
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Memory; Middle Aged; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2010 |
Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Delayed-Action Preparations; Donepezil; Female; Galantamine; Humans; Indans; Male; Patient Satisfaction; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2011 |
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disabled Persons; Donepezil; Female; Galantamine; Humans; Indans; Linear Models; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2012 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Longitudinal Studies; Male; Memantine; Mental Disorders; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine | 2014 |
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Comorbidity; Donepezil; Female; Galantamine; Humans; Indans; Italy; Male; Memantine; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome | 2014 |
Antidementia drug treatment in people screened positive for dementia in primary care.
Topics: Aged; Aged, 80 and over; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Mental Status Schedule; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Primary Health Care; Rivastigmine | 2015 |
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Ethnicity; Female; Galantamine; Humans; Indans; Indiana; Male; Medication Adherence; Piperidines; Rivastigmine | 2017 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitors; Cognition; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Indans; Indoles; Male; Middle Aged; Piperidines; Rivastigmine; Serotonin Antagonists; Treatment Failure | 2018 |
158 other study(ies) available for rivastigmine and galantamine
| Article | Year |
|---|---|
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
Topics: Acetylcholinesterase; Alkaloids; Butyrylcholinesterase; Cholinesterase Inhibitors; Cyclic N-Oxides; Humans; Isomerism; Oxazines; Structure-Activity Relationship | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
Topics: Acetylcholinesterase; Amyloid beta-Protein Precursor; Benzofurans; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Neurons; Oxepins; Structure-Activity Relationship | 2005 |
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
Topics: Acetophenones; Acetylcholinesterase; Animals; Benzofurans; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Furans; Heterocyclic Compounds, 3-Ring; Humans; Models, Molecular; Oxepins; Stereoisomerism; Structure-Activity Relationship; Torpedo | 2006 |
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Phenylcarbamates; Physostigmine; Rivastigmine; Serotonin | 2006 |
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Humans; Ligands; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Polyamines; Protein Binding; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Computational Biology; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Tacrine | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concentration 50; Models, Biological; Models, Molecular; Molecular Structure; Pyrans | 2011 |
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Topics: Alkaloids; Amyloid beta-Protein Precursor; Animals; Brain; Cell Death; Cell Line; Chromatography, Affinity; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Dioxoles; Dyrk Kinases; Glutamic Acid; Humans; Imidazoles; In Vitro Techniques; Mice; Models, Molecular; Molecular Structure; Neuroprotective Agents; Porifera; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2012 |
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Coumarins; Horses; Humans | 2013 |
Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Carbamates; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Halogenation; Hep G2 Cells; Humans; Molecular Docking Simulation; Structure-Activity Relationship; Thiazoles | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; Neurons; Neuroprotective Agents; Nicotine; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate | 2014 |
Salicylanilide diethyl phosphates as cholinesterases inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Esters; Inhibitory Concentration 50; Salicylanilides | 2015 |
A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.
Topics: Acetylcholinesterase; Animals; Binding Sites; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Molecular Docking Simulation; Molecular Structure; Pyrans; Stereoisomerism; Structure-Activity Relationship | 2015 |
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Computer Simulation; Coumarins; Drug Evaluation, Preclinical; Galantamine; Humans; Hydrogen Peroxide; Male; Mice, Inbred BALB C; Models, Molecular; Neuroprotective Agents; Neurotoxicity Syndromes | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
Synthesis, anticholinesterase activity and molecular modeling study of novel carbamate-substituted thymol/carvacrol derivatives.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cymenes; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Monoterpenes; Structure-Activity Relationship; Thermodynamics; Thymol | 2017 |
Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity.
Topics: Acetylation; Acetylcholinesterase; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Fungi; Halogenation; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Mycoses; Phenylalanine | 2017 |
The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
Topics: Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Crystallography, X-Ray; Drug Design; Female; Humans; Kinetics; Male; Mice; Models, Molecular; Protein Binding; Protein Conformation; Rats; Safety; Thermodynamics; Tissue Distribution | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
Topics: Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Discovery; Humans; Inhibitory Concentration 50; Isoquinolines; Molecular Docking Simulation; Structure-Activity Relationship | 2020 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine; Tacrine | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine | 2000 |
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep | 2001 |
Featured CME topic: dementia. Medication update.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interactions; Ergoloid Mesylates; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plants, Medicinal; Rivastigmine | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Treatment Outcome | 2001 |
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Rivastigmine | 2001 |
The impact of journal advertisements on prescribers of cholinesterase inhibitors.
Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publishing; Random Allocation; Rivastigmine | 2002 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents | 2002 |
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Topics: Allosteric Regulation; Animals; Carbamates; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Mice; Neurons; Phenylcarbamates; Piperidines; Receptors, Muscarinic; Receptors, Nicotinic; Recombinant Fusion Proteins; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Editorial comment--How to treat vascular dementia?
Topics: Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2003 |
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic | 2004 |
[Acetylcholinesterase inhibitors].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Galantamine; Humans; Phenylcarbamates; Rivastigmine | 2003 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2004 |
Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Donepezil; Drug Synergism; Electric Stimulation; Galantamine; In Vitro Techniques; Indans; Male; Muscle Contraction; Muscle, Smooth; Nicotine; Nicotinic Agonists; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Wistar; Receptors, Purinergic; Rivastigmine; Stimulation, Chemical; Synaptic Transmission; Tacrine; Vas Deferens | 2004 |
Switching from donepezil or rivastigmine to galantamine in clinical practice.
Topics: Alzheimer Disease; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2004 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity | 2005 |
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Binding, Competitive; Cholinergic Agents; Cholinesterase Inhibitors; Dichlorvos; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Membrane Potentials; Models, Biological; Nicotine; Oocytes; Phenylcarbamates; Physostigmine; Plasmids; Quinolizines; Receptors, Nicotinic; Rivastigmine; Scopolamine; Tacrine; Xenopus laevis | 2005 |
Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
Topics: Aconitine; Amyloid beta-Peptides; Apoptosis; Benzopyrans; Cell Culture Techniques; Cell Line, Tumor; Cholinesterase Inhibitors; Chromones; Donepezil; Dose-Response Relationship, Drug; Enzyme Inhibitors; Galantamine; Humans; Indans; L-Lactate Dehydrogenase; Morpholines; Neuroblastoma; Neuroprotective Agents; Nicotine; Nitriles; Okadaic Acid; Phenylcarbamates; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Nicotinic; Rivastigmine | 2005 |
UK government guidance on Alzheimer's drugs postponed.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Acid Antagonists; Federal Government; Galantamine; Government Regulation; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United Kingdom | 2005 |
Behavioral and neuropsychiatric outcomes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Humans; Mental Disorders; Phenylcarbamates; Prevalence; Rivastigmine | 2005 |
Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; European Union; Galantamine; Humans; Indans; Memantine; Neurotransmitter Agents; Phenylcarbamates; Piperidines; Reimbursement Mechanisms; Rivastigmine | 2006 |
[Advances in Alzheimer's disease treatment].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine | 2006 |
[Cholinesterase inhibitor therapy in long term care settings].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Neuroprotective Agents; Nootropic Agents; Patient Selection; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors | 2006 |
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States | 2006 |
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Utilization; Female; Galantamine; Homes for the Aged; Humans; Indans; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine | 2006 |
Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Doping in Sports; Ethylamines; Female; Galantamine; Growth Hormone; Humans; Indans; Indoles; Phenylcarbamates; Piperidines; Rivastigmine; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry; Urinalysis | 2006 |
The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.
Topics: Amnesia; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Donepezil; Dose-Response Relationship, Drug; Ethylenediamines; Fluorescent Dyes; Galantamine; Indans; Injections, Intraventricular; Lipid Peroxidation; Male; Maze Learning; Mice; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Phenols; Phenylcarbamates; Piperidines; Receptors, sigma; Rivastigmine; Sulfoxides; Xylenes | 2006 |
Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Chronic Disease; Cross-Over Studies; Donepezil; Female; Galantamine; Humans; Indans; Logistic Models; Male; Phenylcarbamates; Piperidines; Respiratory Tract Diseases; Rivastigmine | 2006 |
Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Clinical Trials as Topic; Data Interpretation, Statistical; Donepezil; Female; Galantamine; Humans; Indans; Lewy Body Disease; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome | 2007 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2007 |
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Autopsy; Cerebral Cortex; Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Donepezil; Drug Evaluation; Female; Galantamine; Humans; Indans; Lewy Body Disease; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine; Tacrine; tau Proteins; Tauopathies | 2007 |
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Administration Schedule; Female; Galantamine; Health Surveys; Homes for the Aged; Humans; Indans; Male; Mental Status Schedule; Neuropsychological Tests; Phenylcarbamates; Piperidines; Retention, Psychology; Rivastigmine; Survival Analysis; Treatment Outcome | 2008 |
Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Poison Control Centers; Retrospective Studies; Rivastigmine; Tacrine | 2007 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; Galantamine; Humans; Indans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Jurisprudence; Phenylcarbamates; Piperidines; Rivastigmine; State Medicine; Time Factors; United Kingdom | 2007 |
Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Drug Interactions; Female; Formularies as Topic; France; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; United Kingdom | 2007 |
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Data Interpretation, Statistical; Dibenzothiazepines; Donepezil; Endpoint Determination; Female; Galantamine; Humans; Indans; Long-Term Care; Male; Neuropsychological Tests; Nootropic Agents; Olanzapine; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Retrospective Studies; Risperidone; Rivastigmine; Treatment Outcome | 2007 |
Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Palliative Care; Phenylcarbamates; Piperidines; Prognosis; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2008 |
AAFP and ACP release guideline on dementia treatment.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Guidelines as Topic; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2008 |
Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Europe; Galantamine; Health Policy; Humans; Indans; Insurance, Health, Reimbursement; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Prevalence; Rivastigmine | 2008 |
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Drug Costs; Female; Follow-Up Studies; Galantamine; Health Care Costs; Humans; Indans; Male; Multivariate Analysis; Patient Compliance; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Retrospective Studies; Rivastigmine | 2008 |
Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.
Topics: Animals; Brain; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; Galantamine; In Vitro Techniques; Indans; Male; Neurons; PC12 Cells; Phenylcarbamates; Piperidines; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Rivastigmine | 2008 |
Drug utilization review of cholinesterase inhibitors in Quebec.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Utilization Review; Galantamine; Humans; Indans; Middle Aged; Phenylcarbamates; Piperidines; Quebec; Rivastigmine | 2008 |
Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.
Topics: Adult; Alzheimer Disease; Benzylamines; Buffers; Cholinesterase Inhibitors; Chromatography, Micellar Electrokinetic Capillary; Drug Monitoring; Galantamine; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Phosphoric Acids; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Solvents; Surface-Active Agents | 2009 |
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines.
Topics: Acetylcholinesterase; Cell Line; Cholinesterase Inhibitors; DNA; DNA-Binding Proteins; Donepezil; Galantamine; Gene Expression Regulation; Heat Shock Transcription Factors; Heat-Shock Response; HSP70 Heat-Shock Proteins; Humans; Indans; Macrophages; Neurons; Phenylcarbamates; Phosphorylation; Piperidines; Protein Binding; Regulatory Sequences, Nucleic Acid; Rivastigmine; RNA, Messenger; Time Factors; Transcription Factors | 2009 |
Inhibitory potency of choline esterase inhibitors on acetylcholine release and choline esterase activity in fresh specimens of human and rat neocortex.
Topics: Acetylcholine; Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Galantamine; Humans; In Vitro Techniques; Indans; Middle Aged; Neocortex; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine; Young Adult | 2009 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Cytoprotection; Disease Progression; Donepezil; Drug Synergism; Drug Therapy, Combination; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Neural Pathways; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Delayed-Action Preparations; Dementia; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Medication Adherence; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Drug-induced sialorrhoea and excessive saliva accumulation.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Clozapine; Deglutition Disorders; Donepezil; Galantamine; Humans; Hypnotics and Sedatives; Indans; Phenylcarbamates; Pilocarpine; Piperidines; Quality of Life; Risperidone; Rivastigmine; Sialorrhea | 2009 |
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Economics; Galantamine; Humans; Income; Indans; India; Memantine; Mexico; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United States | 2009 |
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Rivastigmine; Socioeconomic Factors; Spain; Surveys and Questionnaires | 2009 |
Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.
Topics: Acetylcholinesterase; Alkaloids; Animals; Antidotes; Chemical Warfare Agents; Donepezil; Dose-Response Relationship, Drug; Galantamine; Guinea Pigs; Indans; Lethal Dose 50; Male; Phenylcarbamates; Piperidines; Poisoning; Rivastigmine; Sesquiterpenes; Soman; Time Factors; Toxicity Tests, Acute | 2009 |
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Galantamine; Heart Rate; Hospitals, Veterans; Humans; Incidence; Indans; Massachusetts; Nootropic Agents; Phenylcarbamates; Piperidines; Risk; Rivastigmine; Veterans | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors | 2009 |
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Genetic Variation; Genotype; Humans; Indans; Italy; Male; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.
Topics: Alzheimer Disease; Analysis of Variance; Blood Cells; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Gene Expression Regulation; Genome-Wide Association Study; Humans; Indans; Microarray Analysis; Phenylcarbamates; Piperidines; Principal Component Analysis; Rivastigmine; RNA | 2010 |
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Drug Utilization; Female; Galantamine; Geriatric Assessment; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Rivastigmine; Socioeconomic Factors | 2010 |
Anticholinesterase duration in the Australian veteran population.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Medication Adherence; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome; Veterans | 2010 |
Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Kaplan-Meier Estimate; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Severity of Illness Index; Sex Factors; Sweden | 2011 |
Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Predictive Value of Tests; Retrospective Studies; Rivastigmine; Treatment Outcome | 2010 |
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Observer Variation; Phenylcarbamates; Piperidines; Plant Extracts; Rivastigmine; Spain; Substance-Related Disorders | 2010 |
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Medication Adherence; Netherlands; Phenylcarbamates; Retrospective Studies; Rivastigmine | 2010 |
Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Multivariate Analysis; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2011 |
[Prescription differences of dementia drugs in urban and rural areas in Germany].
Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; Indans; Medically Underserved Area; Memantine; Neuropsychiatry; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Rivastigmine; Rural Population; Urban Population; Workforce | 2011 |
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cytochrome P-450 CYP2D6; Donepezil; Female; Galantamine; Genetic Association Studies; Genetic Variation; Genotype; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2011 |
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk; Rivastigmine | 2011 |
Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anesthesia, General; Cholinesterase Inhibitors; Cohort Studies; Critical Care; Dementia; Donepezil; Female; Galantamine; Hip Fractures; Humans; Indans; Male; Outcome and Process Assessment, Health Care; Phenylcarbamates; Piperidines; Pneumonia; Postoperative Complications; Respiratory Insufficiency; Resuscitation; Risk; Rivastigmine | 2011 |
Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Donepezil; Drug Stability; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenethylamines; Phenols; Phenylcarbamates; Piperidines; Plasma; Reference Standards; Reproducibility of Results; Rivastigmine; Tandem Mass Spectrometry | 2012 |
Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Catalase; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Glutathione Reductase; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Rivastigmine | 2012 |
[New anti-AD drugs--their possibilities and issues].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; N-Methylaspartate; Phenylcarbamates; Rivastigmine | 2012 |
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Heart; Humans; Indans; Male; Phenylcarbamates; Piperidines; Rivastigmine | 2012 |
Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.
Topics: Acetylcholinesterase; Animals; Binding Sites; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Electrophorus; Galantamine; Models, Molecular; Molecular Docking Simulation; Phenylcarbamates; Rivastigmine; Salicylanilides; Structure-Activity Relationship | 2012 |
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrioventricular Block; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Galantamine; Hospitalization; Humans; Incidence; Male; Netherlands; Phenylcarbamates; Poisson Distribution; Proportional Hazards Models; Risk; Rivastigmine; Syncope | 2012 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Male; Medical Records; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Rivastigmine; Sweden; Treatment Outcome | 2013 |
Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Interleukin-1beta; Interleukin-6; Male; Phenylcarbamates; Piperidines; Rivastigmine; Sex Factors; Tumor Necrosis Factor-alpha | 2013 |
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Home Care Services; Humans; Indans; Linear Models; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Treatment Outcome | 2013 |
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Area Under Curve; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Dementia, Vascular; Donepezil; Drug Prescriptions; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Young Adult | 2013 |
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Donepezil; Drug Monitoring; Drug Prescriptions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Finland; Follow-Up Studies; Galantamine; Guideline Adherence; Humans; Indans; Male; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Proportional Hazards Models; Registries; Rivastigmine | 2014 |
Anti-dementia drugs in a psychiatric hospital for dementia patients.
Topics: Aged; Dementia; Donepezil; Galantamine; Hospitalization; Hospitals, Psychiatric; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2014 |
Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Topics: Animals; Cerebral Cortex; Cognition; Donepezil; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Galantamine; Gamma Rhythm; Indans; Male; Memantine; Motor Activity; Muscarinic Antagonists; Neural Pathways; Nootropic Agents; Phenylcarbamates; Piperidines; Principal Component Analysis; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Signal Processing, Computer-Assisted; Tacrine; Theta Rhythm | 2014 |
Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report.
Topics: Administration, Oral; Aged; Cholinesterase Inhibitors; Drug Eruptions; Galantamine; Humans; Male; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Galantamine; Gene Frequency; Genetic Loci; Genotype; Haplotypes; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine | 2014 |
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Follow-Up Studies; Galantamine; Humans; Longitudinal Studies; Male; Netherlands; Risk Factors; Rivastigmine; Treatment Outcome; Urinary Incontinence | 2015 |
Galantamine improves sleep quality in patients with dementia.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Indans; Male; Piperidines; Rivastigmine; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2015 |
Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cohort Studies; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Pneumonia; Retrospective Studies; Risk Assessment; Rivastigmine | 2015 |
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
Topics: Aged; Cholinesterase Inhibitors; Comorbidity; Databases, Factual; Dementia; Donepezil; Female; Galantamine; Health Services Research; Humans; Indans; Male; Ontario; Pacemaker, Artificial; Piperidines; Prosthesis Implantation; Retrospective Studies; Risk; Rivastigmine | 2015 |
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.
Topics: Aged; Aged, 80 and over; Caregivers; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Germany; Humans; Indans; Interviews as Topic; Logistic Models; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Piperidines; Rivastigmine | 2015 |
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.
Topics: Cohort Studies; Dementia; Dihydroergocristine; Dihydroergotamine; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Piperidines; Piracetam; Proportional Hazards Models; Retrospective Studies; Rivastigmine; Taiwan; Time Factors | 2015 |
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Galantamine; Humans; Indans; Male; Medication Errors; North America; Pharmacovigilance; Piperidines; Rivastigmine; World Health Organization | 2015 |
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Japan; Male; Memantine; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome | 2015 |
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; Attitude of Health Personnel; Caregivers; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Memantine; Middle East; Patient Preference; Physicians; Piperidines; Prospective Studies; Rivastigmine | 2015 |
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Databases, Factual; Dementia; Donepezil; Galantamine; Humans; Indans; Pharmacovigilance; Piperidines; Rivastigmine; United States; United States Food and Drug Administration | 2015 |
Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina.
Topics: Animals; Cholinesterase Inhibitors; Convulsants; Donepezil; Galantamine; Indans; Locomotion; Models, Biological; Piperidines; Planarians; Rivastigmine; Seizures; Survival Rate; Tacrine | 2016 |
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Piperidines; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2016 |
Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
Topics: Child; Child, Preschool; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Nootropic Agents; Piperidines; Poison Control Centers; Retrospective Studies; Rivastigmine | 2016 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Eating; Female; Follow-Up Studies; Galantamine; Geriatric Assessment; Humans; Indans; Male; Nutrition Assessment; Nutritional Status; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine | 2016 |
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Indans; Memantine; Mitochondria; Monoamine Oxidase; Nootropic Agents; Oxygen Consumption; Piperidines; Rivastigmine; Swine | 2017 |
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galantamine; Hospitalization; Humans; Indans; Male; Memantine; Middle Aged; Piperidines; Pneumonia; Risk; Rivastigmine | 2017 |
Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Substitution; Galantamine; Humans; Retrospective Studies; Rivastigmine; Treatment Outcome | 2017 |
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Tolerance; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Piperidines; Rivastigmine | 2017 |
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; Memantine; Nootropic Agents; Rivastigmine; Severity of Illness Index; Treatment Outcome; White Matter | 2017 |
Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.
Topics: Aged; Aged, 80 and over; Asian People; Cholinergic Antagonists; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Galantamine; Hawaii; Hospitals, Urban; Humans; Indans; Male; Memantine; Native Hawaiian or Other Pacific Islander; Pacific Islands; Piperidines; Retrospective Studies; Rivastigmine | 2017 |
Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Hydrogen Bonding; Indans; Molecular Conformation; Molecular Dynamics Simulation; Piperidines; Rivastigmine; Torpedo | 2017 |
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Donepezil; Female; Follow-Up Studies; Galantamine; Genotype; Hong Kong; Humans; Male; Pharmacogenetics; Pharmacogenomic Testing; Rivastigmine | 2019 |
[Patterns of antidemential drug use in a group of patients from Colombia].
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colombia; Cross-Sectional Studies; Dementia; Donepezil; Drug Utilization; Female; Galantamine; Humans; Male; Memantine; Middle Aged; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2019 |
Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer's Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cardiotoxicity; Cholinesterase Inhibitors; Donepezil; Galantamine; Heart Conduction System; Heart Rate; Isolated Heart Preparation; Rabbits; Refractory Period, Electrophysiological; Risk Assessment; Rivastigmine; Time Factors | 2020 |
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Hospitalization; Humans; Male; Ontario; Retrospective Studies; Rhabdomyolysis; Risk Assessment; Rivastigmine | 2019 |
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Development; Galantamine; Humans; Memantine; Rivastigmine | 2020 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine | 2020 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Healthcare Disparities; Humans; Male; Medicare; Memantine; Nootropic Agents; Patient Acceptance of Health Care; Rivastigmine; Treatment Outcome; United States | 2020 |
Gas-phase basicity and proton affinity measurements of Alzheimer's disease drugs by the extended kinetic method and a theoretical investigation.
Topics: Alzheimer Disease; Curcumin; Galantamine; Humans; Neuroprotective Agents; Protons; Rivastigmine; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2020 |
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Rivastigmine; Tacrine | 2021 |
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Humans; Memantine; Product Surveillance, Postmarketing; Republic of Korea; Rivastigmine; Universal Health Care | 2021 |
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Finland; Galantamine; Humans; Male; Memantine; Nootropic Agents; Nursing Homes; Retrospective Studies; Rivastigmine; Time-to-Treatment | 2021 |
Multiple cholinesterase inhibitors have antidepressant-like properties in the mouse forced swim test.
Topics: Animals; Antidepressive Agents; Association Learning; Behavior, Animal; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Repositioning; Galantamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; Physostigmine; Rivastigmine; Swimming | 2021 |
Microsequential injection analysis/lab-on-valve system for the automatic evaluation of acetylcholinesterase inhibitors.
Topics: Animals; Cholinesterase Inhibitors; Donepezil; Electrophorus; Flow Injection Analysis; Galantamine; Humans; Molecular Docking Simulation; Reproducibility of Results; Rivastigmine; Structure-Activity Relationship; Xanthones | 2021 |
The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Female; Galantamine; Humans; Male; Nootropic Agents; Pneumonia; Rivastigmine; Sex Factors; United States; United States Food and Drug Administration | 2021 |
Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Galantamine; Humans; Male; Medicare; Muscarinic Antagonists; Retrospective Studies; Rivastigmine; United States; Urinary Bladder, Overactive | 2022 |
A pendant droplet-based sensor for the detection of acetylcholinesterase and its inhibitors.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Galantamine; Limit of Detection; Neostigmine; Rivastigmine | 2021 |
Association between long-term usage of acetylcholinesterase inhibitors and lung cancer in the elderly: a nationwide cohort study.
Topics: Acetylcholinesterase; Aged; Cholinesterase Inhibitors; Cohort Studies; Comorbidity; Galantamine; Humans; Lung Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivastigmine; Taiwan | 2022 |
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2022 |
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Galantamine; Humans; Indans; Male; Medicare; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; United States | 2022 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine; Deglutition Disorders; Donepezil; Galantamine; Humans; Memantine; Penicillamine; Risk Management; Rivastigmine; United States; United States Food and Drug Administration | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2022 |
Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine | 2023 |
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Pandemics; Phenylcarbamates; Piperidines; Prevalence; Retrospective Studies; Rivastigmine | 2023 |